This MedLibrary.org supplementary page on Alitretinoin is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Alitretinoin
|
|
| Systematic (IUPAC) name | |
| (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethyl- 1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid |
|
| Identifiers | |
| CAS number | |
| ATC code | L01 D111 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C20H28O2 |
| Mol. mass | 300.435 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Rx only |
| Routes | Topical |
Alitretinoin (tradename Panretin) is an antineoplastic agent developed by Ligand Pharmaceuticals.
It is a first generation retinoid.
Contents |
Clinical uses
Alitretinoin is indicated for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. It is not indicated when systemic anti-KS therapy is required (e.g., more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement). There is no experience to date using alitretinoin with systemic anti-KS treatment.
History
Ligand gained Food and Drug Administration (FDA) approval for alitretinoin in February 1999.
Vol. 140 No. 12, December 2004 Archives • Online Features
Under the trade name 'Toctino' it has been granted prescription rights in the UK (08/09/2008) for use in Chronic Hand Eczema.
It is manufactured by Basilea of Switzerland. (BAL4079)
Oral Alitretinoin (9-cis-Retinoic Acid) Therapy for Chronic Hand Dermatitis in Patients Refractory to Standard Therapy Results of a Randomized, Double-blind, Placebo-Controlled, Multicenter Trial
Thomas Ruzicka, MD; Frederik Grønhøj Larsen, MD, PhD; Dorota Galewicz, MD; Attila Horváth, MD; Peter Jan Coenraads, MD; Kristian Thestrup-Pedersen, MD; Jean Paul Ortonne, MD; Christos C. Zouboulis, MD; Martin Harsch, PhD; Thomas C. Brown, PhD; Maurice Zultak, MD
Arch Dermatol. 2004;140:1453-1459.
References
- ^ WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. Retrieved on 2008-09-05.
External links
- Prescribing Information (revised February 2007). Retrieved on 01-30-08.
|
||||||||||||||
Wikipedia content modification information:
- This page was last modified on 26 September 2008, at 01:36.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Alitretinoin".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.